Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
Phase 1
- Conditions
- Fibrostenotic Crohn’s diseaseTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-504460-41-00
- Lead Sponsor
- Agomab Spain S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does AGMB-129 target in fibrostenotic Crohn’s disease?
How does AGMB-129’s bioavailability compare to standard-of-care therapies for intestinal fibrosis in Crohn’s?
Which biomarkers correlate with AGMB-129 efficacy in fibrostenotic Crohn’s disease subtypes?
What are the safety profiles of AGMB-129 in Phase I trials for digestive system diseases?
Are there combination therapies or competitor drugs targeting TGF-β pathways for fibrostenotic Crohn’s disease?